A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

计划入组 182 人 · 首次发布于 2025 年 3 月 4 日

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

计划入组 18 人 · 首次发布于 2026 年 2 月 3 日

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

计划入组 470 人 · 首次发布于 2025 年 8 月 6 日

Izalontamab brengitecan

Izalontamab

Bispecific Antibody-Drug Conjugates Show Promise in Solid Tumor Treatment

SystImmune to Present Updated Izalontamab Brengitecan Data for HER2-Negative Breast Cancer at ESMO Breast 2025

Sichuan Biokin's First-in-Class EGFR/HER3 ADC Advances to Phase 3 Trials Across Multiple Cancer Types